NCT04155580 2024-08-02A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)Astex Pharmaceuticals, Inc.Phase 1 Terminated68 enrolled